Compare OGN & CNXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | CNXC |
|---|---|---|
| Founded | 1923 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2020 | 2020 |
| Metric | OGN | CNXC |
|---|---|---|
| Price | $13.43 | $24.67 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $11.40 | ★ $54.80 |
| AVG Volume (30 Days) | ★ 2.6M | 1.3M |
| Earning Date | 05-07-2026 | 03-24-2026 |
| Dividend Yield | 0.60% | ★ 5.79% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.55 | 0.33 |
| Revenue | $6,216,000,000.00 | ★ $9,825,771,000.00 |
| Revenue This Year | $0.45 | $5.29 |
| Revenue Next Year | $1.67 | $2.49 |
| P/E Ratio | ★ $24.42 | $75.91 |
| Revenue Growth | N/A | ★ 2.15 |
| 52 Week Low | $5.69 | $22.05 |
| 52 Week High | $13.49 | $62.14 |
| Indicator | OGN | CNXC |
|---|---|---|
| Relative Strength Index (RSI) | 72.03 | 42.49 |
| Support Level | $10.05 | $24.93 |
| Resistance Level | $13.46 | $34.64 |
| Average True Range (ATR) | 0.05 | 1.62 |
| MACD | -0.11 | -0.25 |
| Stochastic Oscillator | 57.14 | 20.88 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Concentrix Corp is a technology and services company. It designs, implements, and manages end-to-end solutions, including customer experience process optimization, technology development and design engineering, front- and back-office automation, analytics, and business transformation services. The company serves clients across multiple industry verticals, helping them manage customer engagement and operational processes throughout the customer lifecycle. The company operates in a single operating segment. It generates revenue through the provision of technology and services under contractual arrangements. Geographically, the company generates the maximum revenue from the Philippines and the rest from India, the United States, Great Britain, Germany, Canada and Other countries.